Millions of Americans will soon have direct access to popular weight loss drugs at far lower prices than they pay now.

That's due to a deal announced today between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk.

William Brigham has the details.

That's right, Omna. The president said that people who paid directly for this class of weight loss drugs known as GLP-1s, that they would see considerable reductions in price.

The injectable versions would initially cost $350 a month and then drop to $250.

It would cost $150 a month for a soon-to-be-approved oral version. This agreement also guarantees expanded

Medicare and Medicaid coverage for many patients to use these medications. The administration

says the drugs will be available on the direct-to-consumer site known as Trump RX when it's

launched in January and via Medicare next summer.

Our White House correspondent, Liz Landers, spoke to Dr. Mehmet Oz today.

He's the administrator of the Center for Medicare and Medicaid Services.

She spoke to him after the announcement about what this could mean.

$150 for a pill or $250 for an injection, you'll start taking the medication, and then you'll drop

20% of your weight.

You'll have less hypertension, less diabetes.

Because of that, you'll have less heart attacks, less renal failure, less dementia, all the things

that strip the vitality of the American people away.

Medicare patients who are covered will have a monthly co-pay of $50, and the government will pay less than $250 a month.

To qualify, Medicare beneficiaries must have certain medical requirements and conditions.

So for more on this deal and its potential impact, we are joined by Stacey Ducetzina. She's a professor in the

Department of Health Policy at Vanderbilt University. Thank you so much for being here. Before we get

into the specifics of this deal, what is your overall impression? Is this a good deal for consumers?

...